193. プラダー・ウィリ症候群 Disease details / Clinical trials / Drug dev / DR info

ACOMPLIA 20 mg film-coated tablets
   Karolinska University Hospital
      2008   -   EUCTR2007-006305-25-SE   Sweden;
ACTH
   Nationwide Children's Hospital
      2014   -   NCT02368379   United States;
ARD-101
   Aardvark Therapeutics, Inc.
      2022   Phase 2   NCT05153434   United States;
AZP-531
   Alize Pharma
      2015   Phase 2   EUCTR2014-001670-34-FR   France;Italy;Spain;
      2015   Phase 2   EUCTR2014-001670-34-ES   France;Italy;Spain;
      2015   -   EUCTR2014-001670-34-IT   France;Italy;Spain;
   Millendo Therapeutics SAS
      2020   Phase 2;Phase 3   EUCTR2018-003062-13-FR   Belgium;Canada;France;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2018-003062-13-NL   Australia;Belgium;France;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2018-003062-13-GB   Australia;Belgium;France;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2018-003062-13-ES   Belgium;Canada;France;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2018-003062-13-BE   Australia;Belgium;France;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-003062-13-IT   Belgium;Canada;France;Italy;Netherlands;Spain;United Kingdom;United States;
Acylated and unacylated ghrelin dosages
   University Hospital, Toulouse
      2021   -   NCT04768803   -
Anastrozole
   Assistance Publique - Hôpitaux de Paris
      2012   -   NCT01520467   France;
B. lactis B94
   University of Florida
      2017   -   NCT03277157   United States;
Biopsy
   University Hospital, Toulouse
      2009   Phase 4   NCT01298180   France;
Byetta
   Aintree University Hospital NHS Foundation Trust
      2011   -   EUCTR2010-023179-25-GB   United Kingdom;
CBDV Compound
   Montefiore Medical Center
      2020   Phase 2   NCT03848481   United States;
Cannabidiol
   Benuvia Therapeutics Inc.
      2018   Phase 2   NCT02844933   United States;
Cannabidiol Oral Solution
   Benuvia Therapeutics Inc.
      2018   Phase 2   NCT03458416   United States;
Coenzyme Q10
   The Hospital for Sick Children
      2022   Phase 2   NCT03831425   Canada;
D.3.2 Product code where applicable13:
   Millendo Therapeutics SAS
      2019   Phase 2   EUCTR2018-003062-13-IT   Belgium;Canada;France;Italy;Netherlands;Spain;United Kingdom;United States;
DCCR
   Essentialis, Inc.
      2014   Phase 1/Phase 2   NCT02034071   United States;
   Soleno Therapeutics UK Ltd.
      2019   Phase 3   EUCTR2018-004216-22-GB   United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004215-50-GB   United Kingdom;United States;
   Soleno Therapeutics, Inc.
      2019   Phase 3   NCT04086810   -
      2018   Phase 3   NCT03714373   United Kingdom;United States;
      2018   Phase 3   NCT03440814   United Kingdom;United States;
DEXA, blood tests, H.G.P.O, osseous age.
   University Hospital, Toulouse
      2009   Phase 4   NCT01298180   France;
Diazoxide choline controlled-release tablet
   Essentialis, Inc.
      2017   Phase 2   NCT02893618   -
EU/1/06/362/003: 5µg (1 pen)
   Aintree University Hospital NHS Foundation Trust
      2011   -   EUCTR2010-023179-25-GB   United Kingdom;
Eutropin
   LG Life Sciences
      2014   Phase 3   NCT02204163   Korea, Republic of;
Exenatide
   Aintree University Hospital NHS Foundation Trust
      2011   -   EUCTR2010-023179-25-GB   United Kingdom;
   Children's Hospital Los Angeles
      2012   -   NCT01444898   United States;
   Garvan Institute of Medical Research
      2007   -   NCT00551343   Australia;
FE 992097
   Ferring Pharmaceuticals
      2014   Phase 2   NCT01968187   United States;
Fluimucil (acetylcysteine)
   Dutch Growth Research Foundation
      2021   Phase 2;Phase 3   EUCTR2019-000735-61-NL   Netherlands;
Follow-up probiotic
   Fundació Sant Joan de Déu
      2021   Phase 1/Phase 2   NCT04685057   Spain;
Follow-up study of the treated cohort
   University Hospital, Toulouse
      2021   Phase 3   NCT05032326   France;
GENOTROPIN (Somatropin) is a growth hormone treatment. It is an exact copy of the natural growth hormone that our bodies make. The main difference is that GENOTROPIN is man-made.
   Dutch growth research foundation
      2012   -   EUCTR2011-001313-14-NL   Netherlands;
GLWL-01
   GLWL Research Inc.
      2018   Phase 2   NCT03274856   Canada;United States;
Genotonorm Miniquick 0,
   Fundació Parc Taulí
      2017   Phase 4   EUCTR2017-002164-41-ES   Spain;
Genotropin
   Dutch Growth Foundation
      2008   Phase 4   EUCTR2007-004716-31-NL   Netherlands;
   LG Life Sciences
      2014   Phase 3   NCT02204163   Korea, Republic of;
Gold
   Children's Hospital Affiliated to Medical College of Zhejiang University
      2020   Phase 0   ChiCTR2000039618   China;
Growth hormone
   Children's Hospital of Zhejiang University School of Medicine
      2019   Phase 4   ChiCTR1900027464   China;
      2019   -   ChiCTR1900022809   China;
   Corporacion Parc Tauli
      2017   Phase 4   NCT03616509   Spain;
Growth hormone (Genotonorm® or Omnitrope®)
   University Hospital, Toulouse
      2009   Phase 4   NCT01298180   France;
Guanfacine extended release (GXR)
   NYU Langone Health
      2019   Phase 4   NCT04066088   United States;
H01BB02
   Toulouse University Hospital
      -   Phase 3   EUCTR2021-000094-91-FR   France;
   University Hospital Toulouse
      -   Phase 3   EUCTR2019-002385-12-IT   Belgium;France;Germany;Italy;Netherlands;
Humatrope 6 mg/12 mg/24 mg injektiokuiva-aine ja liuotin, liuosta varten
   Oy Eli Lilly Finland Ab
      2007   -   EUCTR2007-000469-39-FI   Finland;
INN Not yet proposed
   Alize Pharma
      2015   Phase 2   EUCTR2014-001670-34-FR   France;Italy;Spain;
      2015   Phase 2   EUCTR2014-001670-34-ES   France;Italy;Spain;
      2015   -   EUCTR2014-001670-34-IT   France;Italy;Spain;
Intranasal Oxytocin (IN-OXT)
   Montefiore Medical Center
      2018   Phase 2   NCT03197662   United States;
      2015   Phase 2   NCT02629991   United States;
Intranasal oxytocin
   University of Florida
      2015   Phase 1   NCT02013258   United States;
Liraglutide
   Novo Nordisk A/S
      2015   Phase 3   NCT02527200   Australia;Canada;France;Italy;Netherlands;New Zealand;Turkey;United States;
   Vancouver General Hospital
      2012   Phase 4   NCT01542242   Canada;
Livoletide
   Millendo Therapeutics SAS
      2020   Phase 2;Phase 3   EUCTR2018-003062-13-FR   Belgium;Canada;France;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2018-003062-13-NL   Australia;Belgium;France;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2018-003062-13-GB   Australia;Belgium;France;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2018-003062-13-ES   Belgium;Canada;France;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2018-003062-13-BE   Australia;Belgium;France;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 2/Phase 3   NCT03790865   Australia;Belgium;France;Italy;Netherlands;Spain;United Kingdom;United States;
METOPROLOL SUCCINATE
   Saniona A/S
      2017   Phase 2   EUCTR2016-003694-18-CZ   Czech Republic;Hungary;
      2016   Phase 2   EUCTR2016-003694-18-HU   Czech Republic;Hungary;
METOPROLOL SUCCINATE (PH. EUR.)
   Saniona A/S
      2022   Phase 2   EUCTR2021-000127-12-SE   Australia;Belgium;France;Ireland;Italy;New Zealand;Spain;Sweden;United Kingdom;United States;
Medical Air vs Oxygen
   The Hospital for Sick Children
      2016   Phase 4   NCT03031626   Canada;
Metoprololsuccinat Orion
   Saniona A/S
      2016   Phase 2   EUCTR2016-003694-18-HU   Czech Republic;Hungary;
Metoprololsuccinat ”Orion”
   Saniona A/S
      2017   Phase 2   EUCTR2016-003694-18-CZ   Czech Republic;Hungary;
Metyrapone
   Nationwide Children's Hospital
      2014   -   NCT02368379   United States;
Norditropin SimpleXx
   Karolinska University Hospital
      2005   -   NCT00372125   Denmark;Norway;Sweden;
Nutropin AQ
   Children's Mercy Hospital Kansas City
      2005   Phase 3   NCT00444964   United States;
OSSITOCINA
   University Hospital Toulouse
      -   Phase 3   EUCTR2019-002385-12-IT   Belgium;France;Germany;Italy;Netherlands;
OT
   University Hospital, Toulouse
      2020   Phase 3   NCT04283578   France;
Octreotide
   Duke University
      2006   -   NCT00399893   United States;
   Oregon Health and Science University
      2005   -   NCT01613495   -
Oxytocin
   Dutch Growth Research Foundation
      2017   Phase 2;Phase 3   EUCTR2017-003423-30-NL   Netherlands;
      2016   Phase 3   EUCTR2016-003820-22-NL   Netherlands;
      2014   Phase 3   EUCTR2013-004134-15-NL   Netherlands;
   Toulouse University Hospital
      -   Phase 3   EUCTR2020-006161-11-FR   France;
   University Hospital Toulouse
      -   Phase 3   EUCTR2019-002385-12-IT   Belgium;France;Germany;Italy;Netherlands;
   University Hospital, Toulouse
      2017   -   NCT03081832   France;
      2016   -   NCT03114371   France;
      2013   Phase 1/Phase 2   NCT02205034   France;
      2011   Phase 1/Phase 2   NCT01548521   France;
   University of Florida
      2017   Phase 1/Phase 2   NCT03245762   United States;
Oxytocin (OXT) continuous
   University Hospital, Toulouse
      2014   Phase 2/Phase 3   NCT02804373   France;
Physiological serum (Sodium chloride)
   University Hospital, Toulouse
      2009   Phase 2   NCT01038570   France;
Pitolisant oral tablets
   Harmony Biosciences, LLC
      2020   Phase 2   NCT04257929   United States;
Probiotic
   Fundació Sant Joan de Déu
      2018   -   NCT03548480   Spain;
R05CB01
   Dutch Growth Research Foundation
      2021   Phase 2;Phase 3   EUCTR2019-000735-61-NL   Netherlands;
RAD011
   Radius Pharmaceuticals, Inc.
      2022   Phase 2/Phase 3   NCT05098509   United States;
RECOMBINANT HUMAN GROWTH HORMON
   Fundació Parc Taulí
      2017   Phase 4   EUCTR2017-002164-41-ES   Spain;
RM-493
   Rhythm Pharmaceuticals, Inc.
      2015   Phase 2   NCT02311673   United States;
Rapamycin
   Peking Union Medical College Hospital
      2021   Phase 0   ChiCTR2000040947   China;
Recombinant Human Growth Hormone (rhGH) Injection
   GeneScience Pharmaceuticals Co., Ltd.
      2018   Phase 3   NCT03554031   China;
Recombinant Somatropin
   Corporacion Parc Tauli
      2014   -   NCT02205450   Spain;
RhGH
   Cai Jinhua
      2021   -   ChiCTR2100046551   China;
   Children's Hospital of Zhejiang University School of Medicine
      2019   Phase 4   ChiCTR1900027464   China;
Rimonabant
   Weill Medical College of Cornell University
      2007   Phase 3   NCT00603109   United States;
Sandostatin LAR
   University of British Columbia
      2004   Phase 3   NCT00175305   Canada;
Saxenda
   Novo Nordisk A/S
      2016   Phase 3   EUCTR2014-004415-37-NL   Australia;Canada;European Union;France;Italy;Netherlands;New Zealand;Turkey;United States;
      2015   Phase 3   EUCTR2014-004415-37-IT   Australia;Canada;European Union;France;Italy;Netherlands;New Zealand;Turkey;United States;
      -   Phase 3   EUCTR2014-004415-37-FR   Australia;Canada;European Union;France;Italy;Netherlands;New Zealand;Turkey;United States;
Somatropin
   Erasmus Medical Center
      2020   Phase 3   NCT04484051   Australia;Netherlands;
   Nagashima Masahito
      2021   Phase 3   JPRN-jRCT2031200351   Japan;
   Novo Nordisk A/S
      2011   Phase 1   NCT01401244   United States;
      2008   -   NCT00705172   Denmark;Germany;Switzerland;
Somatropin - GH naïve pediatric cohort
   Pfizer
      2021   Phase 3   NCT04697381   Japan;
Somatropin - GH treated cohort
   Pfizer
      2021   Phase 3   NCT04697381   Japan;
Somatropin - adult cohort
   Pfizer
      2021   Phase 3   NCT04697381   Japan;
Subcutaneous Beloranib in Suspension
   Zafgen Inc.
      2016   Phase 3   EUCTR2015-000660-33-BE   Belgium;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;
      2015   Phase 3   EUCTR2015-000660-33-FR   Belgium;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;
      2015   Phase 3   EUCTR2015-000660-33-ES   Belgium;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;
      2015   -   EUCTR2015-000660-33-SE   Belgium;Canada;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
Syntocinon
   Centre Hospitalier de Toulouse
      2014   Phase 3   EUCTR2013-004437-33-FR   France;
      -   Phase 2   EUCTR2010-022370-14-FR   France;
   University Hospital of Toulouse
      2016   Phase 3   EUCTR2016-003273-18-FR   France;
Syntocinon nasal spray
   Dutch Growth Research Foundation
      2017   Phase 2;Phase 3   EUCTR2017-003423-30-NL   Netherlands;
      2016   Phase 3   EUCTR2016-003820-22-NL   Netherlands;
      2014   Phase 3   EUCTR2013-004134-15-NL   Netherlands;
Syntocinon®/- Spray
   University Hospital, Toulouse
      2009   Phase 2   NCT01038570   France;
TESOFENSINE CITRATE
   Saniona A/S
      2022   Phase 2   EUCTR2021-000127-12-SE   Australia;Belgium;France;Ireland;Italy;New Zealand;Spain;Sweden;United Kingdom;United States;
Tesofensine/Metoprolol
   Saniona
      2017   Phase 2   NCT03149445   Czechia;
Tesomet
   Saniona
      2021   Phase 2   NCT05198362   United States;
   Saniona A/S
      2022   Phase 2   EUCTR2021-000127-12-SE   Australia;Belgium;France;Ireland;Italy;New Zealand;Spain;Sweden;United Kingdom;United States;
Topiramate
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      -   Phase 3   EUCTR2011-003432-32-FR   France;
   Assistance Publique - Hôpitaux de Paris
      2012   Phase 3   NCT02810483   France;
   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
      2002   -   NCT00065923   United States;
ZGN-440
   Zafgen Inc.
      2016   Phase 3   EUCTR2015-000660-33-BE   Belgium;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;
      2015   Phase 3   EUCTR2015-000660-33-FR   Belgium;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;
      2015   Phase 3   EUCTR2015-000660-33-ES   Belgium;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;
      2015   -   EUCTR2015-000660-33-SE   Belgium;Canada;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
ZGN-440 for Injectable Suspension
   Zafgen, Inc.
      2014   Phase 3   NCT02179151   United States;
ZGN-440 for injectable suspension
   Zafgen, Inc.
      2013   Phase 2   NCT01818921   United States;
ZGN-440 sterile diluent
   Zafgen, Inc.
      2013   Phase 2   NCT01818921   United States;
intranasal carbetocin
   Levo Therapeutics, Inc.
      2018   Phase 3   NCT03649477   Australia;Canada;United States;